Sound waves could make brain tumor diagnosis safer and smarter

NCT ID NCT04940507

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial explores whether focused ultrasound can enhance the release of tumor DNA into the blood and spinal fluid, potentially making liquid biopsies a more reliable way to diagnose brain tumors. Researchers will use MRI-guided focused ultrasound to partially ablate the tumor in about 50 adults with new brain lesions, then collect blood and cerebrospinal fluid samples before and after the procedure. The goal is to see if this approach increases the amount of tumor DNA in circulation and improves the accuracy of molecular subtyping, which could reduce the need for invasive surgical biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Magnetic Resonance-guided Focused Ultrasound (MRgFUS) used to partially ablate brain tumors and enhance liquid biopsy
What this could lead to
If successful, this could make brain tumor diagnosis less invasive and more accurate, potentially reducing the need for risky surgical biopsies.
What could go wrong
This is an early feasibility study with a small number of participants. The technique may not reliably boost tumor DNA levels, and the procedure carries risks like bleeding or neurological complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Toronto Western Hospital, University Health Network

    Toronto, Ontario, M5T 2S8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.